ACLY

Across TCGA pan-cancer cohorts, ACLY RNA differs between tumor and matched normal tissue in 17 of 18 cancer types tested, making tumor–normal expression one of ACLY’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ACLY RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ACLY is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

KIRC, HNSC, and COAD are the cancer types where ACLY tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACLY RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+1.874	<.001	12	view →
HNSC	Male	All	+1.487	<.001	12	view →
COAD	Male	IV	+1.368	<.001	11	view →
BLCA	Female	All	+1.353	<.001	11	view →
LIHC	Female	II,III,IV	+2.195	<.001	9	view →
KICH	Female	II,III,IV	−1.768	<.001	7	view →
LUSC	Male	II,III,IV	+0.806	<.001	7	view →
LUAD	Male	II,III,IV	+0.715	<.001	7	view →
BRCA	All	II,III,IV	+0.569	<.001	6	view →
KIRP	All	All	+0.520	.004	6	view →
CHOL	Male	All	+2.721	<.001	5	view →
STAD	Male	II,III,IV	+1.122	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 17 lineages.

ACLY–KIRC

Open the KIRC breakdown →